Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ieved to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the exact mechanism of action of Duloxetine is unknown, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and older. Duloxetine is not approved for use in pediatric patients.

Important Safety Information

Duloxetine is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Duloxetine is approved only for adults 18 and over.

Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have including kidney problems, glaucoma, or diabetes. Patients should talk to their doctor if they have itching, right upper belly pain, dark urine, yellow skin or eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been repor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 Bloomage BioTechnology ... announces a strategic cooperation with the South Korean BioTech ... a joint venture Medybloom to develop and promote Type ... China . Medytox, the Botulinum ... and is also the fourth company in the world ...
(Date:7/27/2015)... , July 27, 2015   DocResponse ... technology application in a peer-reviewed study , ... triage: audit study", published in the July issue ... study by Harvard Medical School researchers determined that ... DocResponse listing the correct diagnosis first in standardized ...
(Date:7/27/2015)... , Belgium , July 27, ... VNRX), a life sciences company focused on developing blood-based ... and other conditions, today announced that it has engaged ... organization, Global Specimen Solutions, Inc. (GSS), to support initial ... cancer tests. Under the agreement, GSS ...
Breaking Medicine Technology:Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7
... Myocor, Inc. announced that,the U.S. Food and ... Valvular and Ventricular Improvement Via iCoapsys Delivery ... evaluate the,safety and feasibility of the percutaneously ... valve insufficiency caused by left,ventricular dysfunction and ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... lab studies at Mayo Clinic focused,on multiple myeloma. ... Factor 5A gene technology to up-regulate apoptosis of ... for,encapsulation of Factor 5A to enhance the time ...
Cached Medicine Technology:Myocor Receives Approval for Percutaneous Trial 2Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
(Date:7/27/2015)... ... ... With a new charity program in the Chico, CA area, Gary Short & ... of deaths and injuries occurring from police pursuits, and announced that they will be ... police to find better and safer ways to conduct pursuits. To support this wonderful ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they ... that tooth loss can incur a lot of stress, pain, discomfort and embarrassment, which ... The All-On-4™ treatment reaps the benefits of implants with the cost savings of ...
(Date:7/27/2015)... ... , ... In a creative effort to provide clear information about the process ... at Dove Tree in Lubbock has shared a new infographic to illustrate the process. ... Both the nationally recognized collegiate program and traditional adult program at The Ranch at ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... SupplyLogic, a ... executive blog on its newly redesigned company Website. In the blog, Founder and CEO ... of a popular comedian: "Comedian George Wallace always asks: ‘Why is it the closer ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... serving communities in and around Dallas, Texas, is announcing a joint charity effort ... support and employment resources for American veterans who are returning from overseas. , ...
Breaking Medicine News(10 mins):Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 2Health News:Gary Short & Associates in Chico, CA Initiates Charity Campaign to Collaborate with National Nonprofit PursuitSAFETY 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 2Health News:The Ranch At Dove Tree Infographic Enlightens Process Of Recovery 3Health News:SupplyLogic Releases First Executive Blog on Supply Chain Management Issues 2Health News:The Tedesco Agency of North Dallas and Non-Profit IAVA Announce Joint Charity Effort to Support American Veterans 2
... Nearly one in 10 obstetricians in a new study ... emotional toll of stillbirths and infant deaths. , ... survey by researchers at the University of Michigan Health ... toll on them personally. , "Our survey reveals that ...
... to Launch a Program in Support of the Heightened National Response ... ... Platinum selling,singer/songwriter/producer Lyfe Jennings kicked off his Baby I,m a Star,summer concert ... with the tour, Lyfe is partnering with Music World,Entertainment to launch a ...
... to develop rheumatoid arthritis in adulthood as their average ... the Annals of the Rheumatic Diseases . , ... which argues that certain conditions and diseases in adult ... Diabetes, coronary heart disease, and high blood pressure, for ...
... (p. 26). In this second annual,double issue, Newsweek poses ... whether politicians should pander, whether having,children makes you happier ... global warming. Readers can also test their Global IQ ... issue. Try these:, 1. How many presidents achieved ...
... to regulate emotions can determine both neurological and physiological ... University and Rutgers University neuroscientists has discovered. The findings, ... Nature Neuroscience , shed light on how the ... Previous research has demonstrated these strategies can alter responses ...
... a replacement organ that never arrives , , SUNDAY, June ... clinging to life this very second, and their only ... The science of organ transplantation has improved by leaps ... died in 2005, waiting for a replacement organ that ...
Cached Medicine News:Health News:Stillbirths, infant deaths lead to anxiety, guilt and stress among obstetricians 2Health News:Lyfe Jennings Launches Summer Tour and HIV/AIDS Awareness Initiative 2Health News:NEWSWEEK: Media Lead Sheet - July 7-14, 2008 Double Issue (On Newsstands Monday, June 30) 2Health News:NEWSWEEK: Media Lead Sheet - July 7-14, 2008 Double Issue (On Newsstands Monday, June 30) 3Health News:NEWSWEEK: Media Lead Sheet - July 7-14, 2008 Double Issue (On Newsstands Monday, June 30) 4Health News:NEWSWEEK: Media Lead Sheet - July 7-14, 2008 Double Issue (On Newsstands Monday, June 30) 5Health News:NYU, Rutgers study shows how using mental strategies can alter the brain's reward circuitry 2Health News:Organ Donation: An Advancing Science Hindered by Supply Shortages 2Health News:Organ Donation: An Advancing Science Hindered by Supply Shortages 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: